• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在临床实验室中进行胶质母细胞瘤的 MGMT 检测:与甲基化分析的不一致性阻止了常规免疫组织化学的实施。

MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.

机构信息

Cure for Life Foundation for Neuro-Oncology, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Kensington, Australia.

出版信息

J Cancer Res Clin Oncol. 2012 Nov;138(11):1789-97. doi: 10.1007/s00432-012-1312-1. Epub 2012 Sep 18.

DOI:10.1007/s00432-012-1312-1
PMID:22986811
Abstract

PURPOSE

Glioblastoma is a universally fatal cancer of the central nervous system which responds poorly to treatment. MGMT has potential as a predictive biomarker in glioblastoma patients to determine treatment response. However, methods of measuring MGMT are currently unsatisfactory, and as such, use of this marker has not translated well into the clinic. This paper aims to review current methodology of MGMT measurement, with a focus on immunohistochemistry as a potential way forward. TOPICS AND METHODS: Studies of glioma patients where MGMT immunohistochemistry was undertaken, as well as the literature surrounding methylation analyses and the regulation of MGMT, were reviewed.

RESULTS

All methods of measuring MGMT were disputed in some way in the literature. A trend of discordance between methylation analyses and protein analyses was present. There is a lack of standardisation in the measurement of MGMT, and as a result, it seems that there are highly variable results.

CONCLUSIONS

No single method of MGMT analysis has emerged as a clear choice for routine clinical testing of MGMT in glioma patients. Although methylation analyses are favoured, their expense and inaccessibility are barriers to their use in routine clinical practice. More research into immunohistochemistry is needed to determine whether it can serve as a reliable and cost-effective alternative to methylation analyses.

摘要

目的

胶质母细胞瘤是一种普遍致命的中枢神经系统癌症,对治疗反应不佳。MGMT 有可能成为胶质母细胞瘤患者的预测性生物标志物,以确定治疗反应。然而,目前测量 MGMT 的方法并不令人满意,因此,该标志物的使用尚未很好地转化为临床实践。本文旨在回顾目前 MGMT 测量的方法,重点关注免疫组织化学作为一种潜在的前进方向。

主题和方法

回顾了进行 MGMT 免疫组织化学的胶质瘤患者的研究,以及围绕甲基化分析和 MGMT 调节的文献。

结果

在文献中,所有测量 MGMT 的方法都在某种程度上存在争议。甲基化分析和蛋白分析之间存在不一致的趋势。MGMT 的测量缺乏标准化,因此,结果似乎存在高度的可变性。

结论

目前,没有一种 MGMT 分析方法能够成为胶质母细胞瘤患者常规临床检测 MGMT 的明确选择。尽管甲基化分析受到青睐,但它们的费用和不可及性是其在常规临床实践中应用的障碍。需要进一步研究免疫组织化学,以确定它是否可以作为甲基化分析的可靠且具有成本效益的替代方法。

相似文献

1
MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.在临床实验室中进行胶质母细胞瘤的 MGMT 检测:与甲基化分析的不一致性阻止了常规免疫组织化学的实施。
J Cancer Res Clin Oncol. 2012 Nov;138(11):1789-97. doi: 10.1007/s00432-012-1312-1. Epub 2012 Sep 18.
2
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.染色体臂 1p 和 19q 缺失的检测在胶质瘤患者中的诊断准确性和成本效益。
Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2.
3
Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.胶质母细胞瘤中的分子生物标志物:系统评价和荟萃分析。
Int J Mol Sci. 2022 Aug 9;23(16):8835. doi: 10.3390/ijms23168835.
4
Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells.胶质瘤细胞中O6-甲基鸟嘌呤甲基转移酶表达的调控机制
Sci Prog. 2025 Apr-Jun;108(2):368504251345014. doi: 10.1177/00368504251345014. Epub 2025 Jun 16.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Deep learning classification of MGMT status of glioblastomas using multiparametric MRI with a novel domain knowledge augmented mask fusion approach.使用具有新型领域知识增强掩码融合方法的多参数MRI对胶质母细胞瘤的MGMT状态进行深度学习分类。
Sci Rep. 2025 Jan 25;15(1):3273. doi: 10.1038/s41598-025-87803-0.
7
Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.MGMT 基因启动子甲基化状态对高级别胶质瘤患者预后及预测价值的系统评价和荟萃分析。
J Neurooncol. 2011 Nov;105(2):325-35. doi: 10.1007/s11060-011-0594-5. Epub 2011 Apr 27.
8
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
9
AI-driven estimation of O6 methylguanine-DNA-methyltransferase (MGMT) promoter methylation in glioblastoma patients: a systematic review with bias analysis.人工智能驱动的胶质母细胞瘤患者 O6 甲基鸟嘌呤-DNA-甲基转移酶(MGMT)启动子甲基化估计:系统评价与偏倚分析。
J Cancer Res Clin Oncol. 2024 Jan 31;150(2):57. doi: 10.1007/s00432-023-05566-5.
10
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.

引用本文的文献

1
Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.胶质母细胞瘤诊断的进展:整合遗传学、非侵入性采样和先进成像技术
Cancers (Basel). 2025 Jan 2;17(1):124. doi: 10.3390/cancers17010124.
2
Unveiling the role of O(6)-methylguanine-DNA methyltransferase in cancer therapy: insights into alkylators, pharmacogenomics, and others.揭示O(6)-甲基鸟嘌呤-DNA甲基转移酶在癌症治疗中的作用:对烷化剂、药物基因组学及其他方面的见解
Front Oncol. 2024 Jul 11;14:1424797. doi: 10.3389/fonc.2024.1424797. eCollection 2024.
3
MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens.

本文引用的文献

1
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.在 Infinium 甲基化 BeadChip 上对胶质母细胞瘤进行 MGMT 甲基化分析,确定了与基因沉默和预后相关的两个不同的 CpG 区域,从而产生了一个预测模型,可用于跨数据集、肿瘤分级和 CIMP 状态进行比较。
Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19.
2
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.在一项新诊断胶质母细胞瘤的前瞻性试验中,三种不同的 MGMT 启动子甲基化分析方法的预后价值。
PLoS One. 2012;7(3):e33449. doi: 10.1371/journal.pone.0033449. Epub 2012 Mar 13.
3
MGMT 在胰腺神经内分泌肿瘤-G2 中经常失活,与 STZ 为基础的治疗方案的治疗活性相关。
Sci Rep. 2023 May 9;13(1):7535. doi: 10.1038/s41598-023-34666-y.
4
Prospective Evaluation of -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors.分化型神经内分泌肿瘤中启动子甲基化状态的前瞻性评估及其与替莫唑胺为基础的化疗疗效的相关性。
Curr Oncol. 2023 Jan 18;30(2):1381-1394. doi: 10.3390/curroncol30020106.
5
Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study.启动子甲基化作为原发性胶质母细胞瘤的预后因素:一项单机构观察性研究
Biomedicines. 2022 Aug 20;10(8):2030. doi: 10.3390/biomedicines10082030.
6
TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas.TMEFF2启动子高甲基化是胶质瘤中一个不良的预后标志物。
Cancer Cell Int. 2021 Mar 4;21(1):148. doi: 10.1186/s12935-021-01818-x.
7
MGMT Status as a Clinical Biomarker in Glioblastoma.MGMT 状态作为胶质母细胞瘤的临床生物标志物。
Trends Cancer. 2020 May;6(5):380-391. doi: 10.1016/j.trecan.2020.02.010. Epub 2020 Mar 27.
8
Do we really know who has an methylated glioma? Results of an international survey regarding use of analyses for glioma.我们真的知道谁患有甲基化胶质瘤吗?一项关于胶质瘤分析方法使用情况的国际调查结果。
Neurooncol Pract. 2020 Jan;7(1):68-76. doi: 10.1093/nop/npz039. Epub 2019 Sep 24.
9
O-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy.O-甲基鸟嘌呤-DNA甲基转移酶(MGMT):胶质瘤化疗中的挑战与新机遇
Front Oncol. 2020 Jan 17;9:1547. doi: 10.3389/fonc.2019.01547. eCollection 2019.
10
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.胶质母细胞瘤中 MGMT 和 EGFR 蛋白表达的特征及其与生存的关系。
J Neurooncol. 2020 Jan;146(1):163-170. doi: 10.1007/s11060-019-03358-x. Epub 2019 Dec 10.
The evolution of personalized cancer genetic counseling in the era of personalized medicine.个性化医学时代的癌症个体化遗传咨询的演变。
Fam Cancer. 2012 Sep;11(3):539-44. doi: 10.1007/s10689-012-9524-8.
4
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.MGMT 启动子甲基化在神经胶质瘤中的评估——焦磷酸测序和定量甲基化特异性 PCR 法。
J Transl Med. 2012 Mar 6;10:36. doi: 10.1186/1479-5876-10-36.
5
Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.100 例胶质母细胞瘤患者中 5 种方法(甲基化特异性聚合酶链反应、MethyLight、焦磷酸测序、甲基化敏感高分辨率熔解和免疫组织化学)分析 O6-甲基鸟嘌呤-DNA-甲基转移酶的比较评估。
Cancer. 2012 Sep 1;118(17):4201-11. doi: 10.1002/cncr.27392. Epub 2012 Jan 31.
6
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.胶质母细胞瘤中 MGMT 启动子甲基化状态与基因和蛋白表达水平的相关性。
Clinics (Sao Paulo). 2011;66(10):1747-55. doi: 10.1590/s1807-59322011001000013.
7
Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.胶质母细胞瘤患者的肿瘤和血清 MGMT 启动子甲基化和蛋白表达。
Clin Transl Oncol. 2011 Sep;13(9):677-85. doi: 10.1007/s12094-011-0714-x.
8
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.全球 DNA 甲基化替代物 LINE-1 甲基化与 MGMT 启动子甲基化相关,是胶质母细胞瘤更好的预后因素。
PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.
9
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.O-甲基鸟嘌呤-DNA 甲基转移酶(MGMT)mRNA 表达预测恶性神经胶质瘤的预后,与 MGMT 启动子甲基化无关。
PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.
10
O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.免疫组织化学检测脑和非脑部全身肿瘤中 O6-甲基鸟嘌呤-DNA 甲基转移酶蛋白表达:与甲基化特异性聚合酶链反应相关性的系统评价和荟萃分析。
BMC Cancer. 2011 Jan 26;11:35. doi: 10.1186/1471-2407-11-35.